C.R. Bard

Rank: 30
2015 Rank26
R&D Spend:$254,700,000
Fiscal year ending:12-31-15
Click here to see all 100

C. R. Bard, Inc. is a multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the product fields of: Vascular, Urology, Oncology and Surgical Specialty. BARD markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities and alternate site facilities.BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs.

Bard Agrees to Acquire Liberator Medical. Bard Agrees to Acquire Full Ownership of its Joint Venture in Japan. Boston Scientific And C. R. Bard Announce Distribution Agreement For Lutonix Drug Coated Balloon.

2015 Top 500 Solar Contractors Key Personnel: Marc Breslawsky, CEO, Imagistics International; Robert Davis, EVP & CFO; Herbert Henkel, CEO, Ingersoll-Rand Company; John Kelly, Controller; Gail Naughton, CEO, Histogen; David Melcher, EVP; John Weiland, COO.;

New Providence, New Jersey